Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxifluridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | TK2 | O00142 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxifluridine SCHEMBL28690558 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL10079621 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL4932137 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL14291576 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL8094 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL14564897 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL12932255 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL8095 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL15060572 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL13300971 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3994 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-10 | — | — | US | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250360219-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | claimed |
| US-20250281417-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-11 | — | — | US | claimed |
| EP-4602052-A1 | PROTEIN-BASED SIGNAL AMPLIFICATION | California Institute of Technology (US) | 2025-08-20 | — | — | EP | claimed |
| US-12383499-B2 | Scale up synthesis of silicasome nanocarriers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-12 | — | — | US | claimed |
| EP-0488718-A2 | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine | Takeda Chemical Industries, Ltd. (JP) | 1992-06-03 | — | — | EP | claimed |
| US-5116600-A | Oxonic acid | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-26 | — | — | US | claimed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | claimed |
| EP-0443028-A1 | NON-INJECTION CARCINOSTATIC AGENT FOR SUPPRESSING OCCURRENCE OF INFLAMMATION DUE TO 5-FLUOROURACIL AND METHOD FOR CURING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-28 | — | — | EP | claimed |
| EP-0189755-B1 | PHARMACEUTICAL COMPOSITION | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-03 | — | — | EP | claimed |
| EP-0189755-A1 | Pharmaceutical composition | F. HOFFMANN-LA ROCHE AG (CH) | 1986-08-06 | — | — | EP | claimed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | claimed |
| EP-0021231-B1 | PROCESS FOR THE PREPARATION OF 5'-DEOXY-5-FLUORO URIDINE AND INTERMEDIATES IN THIS PROCESS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-10-05 | — | — | EP | claimed |
| EP-0021231-A2 | Process for the preparation of 5'-deoxy-5-fluoro uridine and intermediates in this process | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-01-07 | — | — | EP | claimed |
| US-4071680-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-01-31 | — | — | US | claimed |